{"id":"https://openalex.org/W2499795338","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.7021","title":"A multi-institution phase I trial of ruxolitinib in chronic myelomonocytic leukemia (CMML).","display_name":"A multi-institution phase I trial of ruxolitinib in chronic myelomonocytic leukemia (CMML).","publication_year":2015,"publication_date":"2015-05-20","ids":{"openalex":"https://openalex.org/W2499795338","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.7021","mag":"2499795338"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2015.33.15_suppl.7021","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.7021","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.7021","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041754278","display_name":"Eric Padron","orcid":"https://orcid.org/0000-0002-4707-7916","observed_orcids":["https://orcid.org/0000-0002-4707-7916"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric Padron","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035609080","display_name":"Amy Elizabeth Dezern","orcid":"https://orcid.org/0000-0001-5225-4609","observed_orcids":["https://orcid.org/0000-0001-5225-4609"]},"institutions":[{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy Elizabeth Dezern","raw_affiliation_strings":["Sidney Kimmel Comprehensive Cancer Ctr, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sidney Kimmel Comprehensive Cancer Ctr, Baltimore, MD","institution_ids":["https://openalex.org/I4210164401"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046355139","display_name":"Kris Vaddi","orcid":"https://orcid.org/0009-0009-8581-6511","observed_orcids":["https://orcid.org/0009-0009-8581-6511"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kris Vaddi","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018193992","display_name":"Peggy Scherle","orcid":"https://orcid.org/0000-0003-0783-6815","observed_orcids":["https://orcid.org/0000-0003-0783-6815"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peggy A Scherle","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038412368","display_name":"Qing Zhang","orcid":"https://orcid.org/0000-0003-2639-7416","observed_orcids":["https://orcid.org/0000-0003-2639-7416"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qing Zhang","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055823984","display_name":"Yan Ma","orcid":"https://orcid.org/0000-0001-6164-2291","observed_orcids":["https://orcid.org/0000-0001-6164-2291"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yan Ma","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041891985","display_name":"Maria E. Balasis","orcid":"https://orcid.org/0000-0003-1664-3222","observed_orcids":["https://orcid.org/0000-0003-1664-3222"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maria Balasis","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076396878","display_name":"Sara Tinsley","orcid":"https://orcid.org/0000-0003-3012-7398","observed_orcids":["https://orcid.org/0000-0003-3012-7398"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara Tinsley","raw_affiliation_strings":["H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086317353","display_name":"Hanadi Ramadan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hanadi Ramadan","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067324412","display_name":"Casandra Zimmerman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Casandra Zimmerman","raw_affiliation_strings":["Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090527595","display_name":"David P. Steensma","orcid":"https://orcid.org/0000-0001-5130-9284","observed_orcids":["https://orcid.org/0000-0001-5130-9284"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David P. Steensma","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012863731","display_name":"Gail J. Roboz","orcid":"https://orcid.org/0000-0002-0384-3658","observed_orcids":["https://orcid.org/0000-0002-0384-3658"]},"institutions":[{"id":"https://openalex.org/I1340179700","display_name":"NewYork\u2013Presbyterian Hospital","ror":"https://ror.org/03gzbrs57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1340179700"]},{"id":"https://openalex.org/I205783295","display_name":"Cornell University","ror":"https://ror.org/05bnh6r87","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gail J. Roboz","raw_affiliation_strings":["Weill Medical College of Cornell University and the New York Presbyterian Hospital, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Weill Medical College of Cornell University and the New York Presbyterian Hospital, New York, NY","institution_ids":["https://openalex.org/I1340179700","https://openalex.org/I205783295"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041443589","display_name":"Jeffrey E. Lancet","orcid":"https://orcid.org/0000-0002-7751-7310","observed_orcids":["https://orcid.org/0000-0002-7751-7310"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey E. Lancet","raw_affiliation_strings":["H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066001318","display_name":"Alan F. List","orcid":"https://orcid.org/0000-0002-1647-2972","observed_orcids":["https://orcid.org/0000-0002-1647-2972"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alan F. List","raw_affiliation_strings":["H Lee Moffitt Cancer Ctr and Rsrch Inst, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H Lee Moffitt Cancer Ctr and Rsrch Inst, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055740968","display_name":"Mikkael Aaron Sekeres","orcid":"https://orcid.org/0000-0003-2009-6524","observed_orcids":["https://orcid.org/0000-0003-2009-6524"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mikkael A. Sekeres","raw_affiliation_strings":["Leukemia Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5010075752","display_name":"Rami S. Komrokji","orcid":"https://orcid.org/0000-0002-1876-5269","observed_orcids":["https://orcid.org/0000-0002-1876-5269"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rami S. Komrokji","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"33","issue":"15_suppl","first_page":"7021","last_page":"7021"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9136000275611877,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9136000275611877,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.07880000025033951,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13374","display_name":"Hematological disorders and diagnostics","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2711","display_name":"Emergency Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.968999981880188},{"id":"https://openalex.org/keywords/chronic-myelomonocytic-leukemia","display_name":"chronic myelomonocytic leukemia","score":1.0},{"id":"https://openalex.org/keywords/jak1-2-inhibitor","display_name":"JAK1/2 inhibitor","score":0.8899999856948853},{"id":"https://openalex.org/keywords/myelodysplastic-myeloproliferative-neoplasms","display_name":"myelodysplastic/myeloproliferative neoplasms","score":0.9359999895095825},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7839999794960022},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.6489999890327454},{"id":"https://openalex.org/keywords/splenomegaly","display_name":"splenomegaly","score":0.7590000033378601},{"id":"https://openalex.org/keywords/b-symptoms","display_name":"B symptoms","score":0.9070000052452087},{"id":"https://openalex.org/keywords/hematological-response","display_name":"hematologic response","score":0.6380000114440918},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.6539999842643738},{"id":"https://openalex.org/keywords/jak2-mutation","display_name":"JAK2 mutation","score":0.45899999141693115},{"id":"https://openalex.org/keywords/cytokine-profiling","display_name":"cytokine profiling","score":0.46000000834465027}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9417769908905029},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.7471936941146851},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7119015455245972},{"id":"https://openalex.org/C2781087989","wikidata":"https://www.wikidata.org/wiki/Q1682044","display_name":"Monocytosis","level":3,"score":0.6835013628005981},{"id":"https://openalex.org/C2777928532","wikidata":"https://www.wikidata.org/wiki/Q1088072","display_name":"Chronic myelomonocytic leukemia","level":4,"score":0.6258805990219116},{"id":"https://openalex.org/C2781107747","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative neoplasm","level":4,"score":0.543505072593689},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5222431421279907},{"id":"https://openalex.org/C2780240888","wikidata":"https://www.wikidata.org/wiki/Q6052586","display_name":"International Prognostic Scoring System","level":4,"score":0.44718727469444275},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.42464566230773926},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.4230152368545532},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.39405179023742676},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3929292857646942},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3691027760505676},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.3565278649330139},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.32909858226776123},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.2408352792263031},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2063218653202057}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2015.33.15_suppl.7021","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.7021","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.7021","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.7099999785423279,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2267858353","https://openalex.org/W2782003609","https://openalex.org/W4310102731","https://openalex.org/W3180635065","https://openalex.org/W2984309733","https://openalex.org/W2903879969","https://openalex.org/W2522955272","https://openalex.org/W2909890633","https://openalex.org/W4405049117","https://openalex.org/W3025917731"],"abstract_inverted_index":{"7021":[0],"Background:":[1],"CMML":[2,58,320],"is":[3,309,334],"a":[4,78,95,189,241,255],"lethal":[5],"myelodysplastic/myeloproliferative":[6],"neoplasm":[7],"(MDS/MPN)":[8],"characterized":[9],"by":[10,159,171],"peripheral":[11],"monocytosis":[12],"and":[13,43,77,121,135,143,153,166,184,237],"bone":[14],"marrow":[15],"(BM)":[16],"dysplasia":[17],"with":[18,54,100,145,207,252,266,321,326],"limited":[19],"therapeutic":[20,30],"options.":[21],"Preclinical":[22],"studies":[23],"have":[24],"identified":[25],"the":[26,34,41,172,297,339],"JAK2":[27],"inhibitors":[28],"as":[29],"candidates.":[31],"We":[32,312],"conducted":[33],"first":[35],"phase":[36,304,331],"1":[37],"clinical":[38],"trial":[39,346],"exploring":[40],"safety":[42],"efficacy":[44,340],"of":[45,85,164,219,249,263,284,299,307,341],"ruxolitinib,":[46],"an":[47,72],"FDA":[48],"approved":[49],"JAK1/2":[50],"inhibitor,":[51],"in":[52,109,259,281,287,319,324,343],"patients":[53,139],"CMML.":[55,344],"Methods:":[56],"All":[57],"WHO":[59],"subtypes":[60],"were":[61,92,115,141,199],"included":[62,71],"without":[63],"regard":[64],"to":[65,106,117,336],"previous":[66],"therapy.":[67],"Key":[68],"exclusion":[69],"criteria":[70,161],"ANC":[73],"<":[74,81],"0.25x103":[75],"c/dL":[76],"platelet":[79],"count":[80],"35x103c/dL.":[82],"The":[83,124,147,216,302],"use":[84],"GM-CSF":[86],"analogs":[87],"was":[88,126,150,221,278],"prohibited.":[89],"Four":[90],"cohorts":[91],"enrolled":[93,142],"using":[94],"\u201crolling":[96],"six\u201d":[97],"study":[98,125,333],"design,":[99],"doses":[101],"ranging":[102],"from":[103],"5mg":[104,110],"BID":[105,108],"20mg":[107,310],"dose":[111,194,306],"escalations.":[112],"Descriptive":[113],"statistics":[114],"used":[116],"report":[118],"baseline":[119],"characteristics":[120],"response":[122,243],"rates.":[123],"registered":[127],"at":[128,296],"clinicaltrials.gov":[129],"NCT01776723":[130],"Results:":[131],"Between":[132],"March":[133],"2013":[134],"January":[136],"2015,":[137],"19":[138],"(pts)":[140],"treated":[144],"ruxolitinib.":[146,276],"Median":[148],"age":[149],"71":[151],"years":[152],"all":[154],"pts":[155,165,179,186,229,251,265],"had":[156,168,203,234,240,254,269],"CMML-1.":[157],"MPN-CMML":[158],"FAB":[160],"constituted":[162],"67%":[163],"47%":[167],"higher-risk":[169],"disease":[170,327],"Global":[173],"MD":[174],"Anderson":[175],"Scoring":[176],"System.":[177],"Eleven":[178],"(58%)":[180],"received":[181,188],"prior":[182,190],"therapy":[183,220],"8":[185],"(42%)":[187],"hypomethylating":[191],"agent.":[192],"No":[193],"limiting":[195],"toxicities":[196],"for":[197,231],"ruxolitinib":[198,308,315,342],"identified.":[200],"One":[201],"subject":[202],"Grade":[204],"(G)3":[205],"thrombocytopenia":[206],"no":[208,279],"other":[209],"drug-associated":[210],"G3":[211],"or":[212,272],"G4":[213],"adverse":[214],"events.":[215],"mean":[217],"duration":[218],"122":[222],"days":[223],"(range,":[224],"28-409":[225],"days).":[226],"Of":[227],"15":[228,264],"evaluable":[230],"response,":[232],"3":[233],"hematologic":[235],"improvement":[236],"one":[238],"pt":[239],"partial":[242],"per":[244],"2006":[245],"IWG":[246],"criteria.":[247],"Six":[248],"9":[250],"splenomegaly":[253],">":[256],"50%":[257],"reduction":[258],"spleen":[260],"size.":[261],"Fourteen":[262],"reported":[267],"B-symptoms":[268],"clinically":[270],"meaningful":[271],"complete":[273],"resolution":[274],"on":[275],"There":[277],"change":[280],"allelic":[282],"burden":[283],"somatic":[285],"mutations":[286],"responders;":[288],"broad":[289],"spectrum":[290],"cytokine":[291],"profiling":[292],"will":[293],"be":[294],"available":[295],"time":[298],"presentation.":[300],"Conclusions:":[301],"recommended":[303],"2":[305,332],"BID.":[311],"demonstrate":[313],"that":[314],"has":[316],"promising":[317],"activity":[318],"particular":[322],"benefit":[323],"those":[325],"related":[328],"B-symptoms.":[329],"A":[330],"planned":[335],"further":[337],"test":[338],"Clinical":[345],"information:":[347],"NCT01776723.":[348]},"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-08-23T00:00:00"}